Complexin-3 Inhibitors

Chemical inhibitors of Complexin-3 can impede its function primarily through their actions on the SNARE complex and calcium channels, which are critical to the vesicle fusion process that Complexin-3 regulates. Tetanus toxin disrupts the SNARE complex by cleaving its components: synaptobrevin, SNAP-25, and VAMP, respectively. Without an intact SNARE complex, the regulatory role of Complexin-3 in neurotransmitter release is indirectly inhibited because it cannot stabilize the SNARE complex in its "clamped" state, preventing vesicle docking and fusion.

In addition to SNARE complex disruption, the function of Complexin-3 can be indirectly inhibited by modulating calcium influx into the nerve terminal. Chemicals like Conotoxin GVIA, ω-Conotoxin MVIIC, ω-Agatoxin IVA, and antibodies associated with Lambert-Eaton Myasthenic Syndrome target and inhibit various types of voltage-gated calcium channels. By doing so, they reduce the intracellular calcium concentration required for synaptic vesicle fusion. Complexin-3, whose activity is contingent upon calcium-triggered synaptic vesicle exocytosis, would be functionally inhibited due to the reduced availability of calcium to trigger the fusion process. Additional chemicals like Bafilomycin A1 and Dynasore interfere with other aspects of vesicle cycling; Bafilomycin A1 inhibits the V-ATPase proton pump, necessary for vesicle acidification and neurotransmitter loading, while Dynasore inhibits dynamin, essential for vesicle scission from the plasma membrane. Both of these processes are prerequisites for the vesicle fusion that Complexin-3 facilitates. Lastly, Tetraethylammonium works by blocking potassium channels, which are essential for maintaining the neuronal excitability and subsequent calcium dynamics that underpin the vesicle release process governed by Complexin-3.